SNO 2020: The ERC1671 Vaccine Shows Promise in Recurrent GBM
The vaccine is being evaluated in bevacizumab-naïve and -resistant patients.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.